<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="185">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103127</url>
  </required_header>
  <id_info>
    <org_study_id>CYN13-PCAP-AS-SK02</org_study_id>
    <nct_id>NCT02103127</nct_id>
  </id_info>
  <brief_title>Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars</brief_title>
  <official_title>Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess treatment of facial acne scars using the 755nm
      Alexandrite Laser with lens arrays.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To compare severity post treatment using a grading scale for acne scars.</measure>
    <time_frame>3 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction Questionnaire</measure>
    <time_frame>3 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigator and subject will complete satisfaction questionnaire at follow up visits</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acne Scars</condition>
  <arm_group>
    <arm_group_label>755nm Alexandrite laser with lens array</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm Alexandrite laser with lens array</intervention_name>
    <arm_group_label>755nm Alexandrite laser with lens array</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy male or female between 18 and 65 years old

          2. Has unwanted acne scars, excluding ice pick scars (Deep atrophic scars that resemble
             poked holes), and wishes to undergo laser treatments.

          3. Is willing to consent to participate in the study.

          4. Is willing to comply with all requirements of the study including biopsies, being
             photographed, following post treatment care and attending all treatment and follow up
             visits.

        Exclusion Criteria:

          1. The subject is female and pregnant, has been pregnant within the last 3 months, is
             currently breast feeding or planning a pregnancy during the study period.

          2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.

          3. The subject has active or localized systemic infections.

          4. The subject has a coagulation disorder or is currently using anti-coagulation
             medication (including but not limited to heavy aspirin therapy {greater than 81 mg
             per day}).

          5. The subject has any condition which, in the investigator's opinion, would make it
             unsafe for the subject to participate in this research study.

          6. The subject is currently enrolled in an investigational drug or device trial, or has
             received an investigational drug or been treated with an investigational device
             within 3 months prior to entering this study.

          7. The subject has used Accutane within 6 months prior to enrollment.

          8. The subject has the need to be exposed to artificial tanning devices or excessive
             sunlight during the trial.

          9. The subject has had prior treatment with parenteral gold therapy (gold sodium
             thiomalate).

         10. The subject has a history of keloids.

         11. The subject has evidence of compromised wound healing.

         12. The subject has a history of squamous cell carcinoma or melanoma.

         13. The subject has a history of immunosuppression/immune deficiency disorders (including
             HIV infection or AIDS) or use of immunosuppressive medications.

         14. The subject has an allergy to lidocaine and epinephrine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of Northern California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
